-
How to see a doctor in an Internet hospital?
Time of Update: 2021-04-27
Xiong Xianjun, Director of the Medical Service Management Department of the National Medical Insurance Administration: The medical and drug expenses incurred by the insured person in the designated "Internet +" medical service follow- up prescriptions in the designated area of the coordination area can be given in accordance with the existing treatment policies of offline medical insurance Payment, with prescriptions outside designated medical institutions, you can also pick up medicines at local designated pharmacies .
-
Fined 18,000 yuan for producing and selling inferior drugs
Time of Update: 2021-04-27
Liaoning New Century Pharmaceuticals was rectified within a time limit due to three issues including the inconsistency between the actual storage conditions of some traditional Chinese medicinal materials and the regulations.
-
Huahai Pharmaceutical's voriconazole for injection was approved for clinical use
Time of Update: 2021-04-27
Voriconazole for injection is a broad-spectrum triazole antifungal drug; the original research company is Pfizer, which was approved for domestic marketing in October 2004.
-
Hengrui SHR6390 plans to be included in the breakthrough therapy CDK4/6 inhibitor melee is about to start
Time of Update: 2021-04-27
The proposed indication is SHR6390 tablets combined with fulvestrant to treat hormone receptors that have progressed after endocrine therapy ( HR) positive, human epidermal growth factor receptor 2 (HER2) negative recurrent or metastatic breast cancer, the publication date ends on March 24.
-
Roche's PD-L1 antibody Tecentriq in the Phase 3 clinical trial of NSCLC patients reached the primary endpoint
Time of Update: 2021-04-27
On March 22, Genentech, a subsidiary of Roche, announced that its PD-L1 antibody Tecentriq (atezolizumab, atelizumab) will be used for the treatment of early stage non-small cell lung cancer (NSCLC) patients in Phase 3 clinical trials.
-
Sinopharm: Medical Device Annual Revenue Announcement
Time of Update: 2021-04-27
Facing the national centralized procurement, the latest strategy is announced According to the announcement of Sinopharm Holdings, in 2020, the strict prevention and control measures adopted by hospitals will restrict the development of daily medical operations and hospitalization services, which will have a phased impact on the sales and product structure of the medical device business.
-
Recombinant new coronavirus fusion protein vaccine, a subsidiary of Joincare Pharmaceuticals, has been approved for clinical use
Time of Update: 2021-04-27
On March 24, Joincare Pharmaceuticals issued an announcement stating that the clinical trial application of the "recombinant new coronavirus fusion protein vaccine" developed by its holding subsidiary Livzumab was approved by the State Food and Drug Administration.
-
Biotech: Adalimumab injection obtained approval for drug supplement application
Time of Update: 2021-04-27
On the 24th, Biotech announced that the company has recently received a "Drug Supplementary Application for Adalimumab Injection (trade name: Glerli®) approved and issued by the National Medical Products Administration ("National Medical Products Administration").
The drug has been approved for new indications and new specifications: polyarticular juvenile idiopathic arthritis (40mg/0.
-
Conba: 1mg finasteride tablets passed the consistency evaluation of generic drugs
Time of Update: 2021-04-27
The sales of 1mg finasteride in the medical terminal market in 2019 was 47.
In 2019, the sales revenue of Hangzhou Kangenbei 1mg finasteride tablets was RMB 2.
73 million in research and development for the consistency evaluation of 1 mg finasteride tablets.
-
Daiichi Sankyo mRNA vaccine DS-5670 Phase I/II clinical trial in Japan begins immunization
Time of Update: 2021-04-27
Recently, Daiichi Sankyo announced that the Phase I/II clinical trial of the novel coronavirus pneumonia (COVID-19) mRNA vaccine (DS-5670) in Japan has begun to vaccinate subjects.
Just recently, Moderna announced that its new-generation vaccine mRNA-1283 has been immunized in the first phase of clinical trials for the first batch of subjects.
-
Mobile phone follow-up visits, mobile phone prescriptions...Internet medical treatment makes it easier to see a doctor
Time of Update: 2021-04-27
Mobile phone follow-up, simple and quick operation Online follow-up consultation saves time and money for patients and their families, saves patients from the pain of boats and cars, and is conducive to postoperative recovery "Hello, Director Chen, I have some cough, what's the matter?" "The feeding tube is placed in the throat, which will cause irritation.
-
AstraZeneca/Mersk’s Lynparza combined with Roche Avastin is recommended in the UK for the treatment of ovarian cancer
Time of Update: 2021-04-27
), used for maintenance treatment of patients with homologous recombination defect (HRD) positive advanced ovarian, fallopian tube and peritoneal cancer that fully or partially respond to first-line platinum-based chemotherapy and bevacizumab.
The US FDA approved the drug for use in advanced ovarian cancer with germline BRCA mutation (gBRCAm) that has received three or more chemotherapies.
-
Jinling Pharmaceutical's ferrous succinate tablets obtained the consistency evaluation of the National Food and Drug Administration
Time of Update: 2021-04-27
On March 23, Jinling Pharmaceutical issued an announcement stating that the branch Jinling Pharmaceutical Factory had recently received a notice of acceptance of the consistency evaluation of ferrous succinate tablets issued by the State Food and Drug Administration.
Jinling Pharmaceutical Factory first obtained the Drug Registration Approval for this product in 2002.
-
Shanghai passed local legislation: Chinese medicine is included in public health emergency management system
Time of Update: 2021-04-27
Encourage pharmaceutical manufacturers, operators of Chinese medicinal materials and Chinese medicinal pieces, medical institutions, and industry associations to establish an information traceability system in accordance with relevant laws, regulations and technical standards.
-
Takeda's "Iatibant Acetate Injection" is about to be approved
Time of Update: 2021-04-27
However, in December 2020, Takeda's Ranarizumab was approved for marketing to prevent the onset of angioedema in HAE patients 12 years of age and older.
Today, Takeda's "Iatibant Acetate Injection" listing application has entered the administrative approval stage, which means that this type of patient may usher in the first acute treatment drug.
-
Renfu Medicine: Mifepristone tablets passed the consistency evaluation of generic drugs
Time of Update: 2021-04-27
, a subsidiary of the company, received the "Drug Supplementary Application Approval Notice" from the State Food and Drug Administration on mifepristone tablets (notice Book number: 2020B05143), the drug passed the generic drug quality and efficacy consistency evaluation.
-
Hisun Pharmaceutical: Epirubicin Hydrochloride for Injection passed the consistency evaluation of generic drugs
Time of Update: 2021-04-27
On March 23, Hisun Pharmaceutical announced that the company's epirubicin hydrochloride for injection has passed the quality and efficacy consistency evaluation of generic drugs.
On May 5, 2019, the State Food and Drug Administration accepted the company's application for the consistency evaluation of epirubicin hydrochloride for injection.
-
Fuan Pharmaceutical: Cefminox sodium for injection passed the consistency evaluation
Time of Update: 2021-04-27
, has recently received a supplementary drug application approval notice issued by the National Medical Products Administration, and its product Cefminox sodium for injection has passed The quality and efficacy consistency evaluation of generic drugs.
Cefminox sodium for injection is an anti-infective drug.
-
Haisco's "Avanafil Tablets" Approved for Listing
Time of Update: 2021-04-27
Yesterday, the official website of the State Food and Drug Administration showed that the avanafil tablets declared by Haisco according to registration classification 3 (domestic applicants imitated the overseas listing but the original research was not listed in the domestic market) have been approved for marketing by NMPA (approval number: National Medicine Standard H20213212 , Sinopharm Zhunzi H20213213), it will be the first imitation of this product after it is marketed.
-
Where is the next leap in CAR-T therapy? Cinda Bio and other Chinese companies explore new directions
Time of Update: 2021-04-27
According to the official website of Reindeer Medical, for patients with relapsed/refractory multiple myeloma, high-dose BCMA targeted CAR-T cell therapy may provide better remission, but the adverse events are more serious.
